ertumaxomab

BIOLOGICAL4 trials

Sponsors

Neovii Biotech, Krankenhaus Nordwest

Conditions

Advanced Breast CancerBreast CancerBreast NeoplasmsHer2/Neu Positive Advanced Solid TumorsMetastatic Breast Cancer

Phase 1

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

TerminatedNCT01569412

Krankenhaus NordwestHer2/Neu Positive Advanced Solid Tumors

Start: 2012-03-31End: 2016-05-31Updated: 2016-05-05

Phase 2

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

TerminatedNCT00351858

Neovii BiotechBreast Cancer, Breast Neoplasms

Start: 2006-07-31End: 2009-02-28Target: 40Updated: 2015-05-01

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

TerminatedNCT00452140

Neovii BiotechAdvanced Breast Cancer, Metastatic Breast Cancer

Start: 2007-03-31End: 2009-02-28Target: 40Updated: 2009-05-19

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

TerminatedNCT00522457

Neovii BiotechAdvanced Breast Cancer, Metastatic Breast Cancer

Start: 2008-01-31End: 2009-12-31Updated: 2011-04-29

Related Papers

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.

2016-07-0748 citations

Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.

Journal of Clinical Oncology2014-05-203 citations